Search results
Results from the WOW.Com Content Network
Superior vena cava syndrome (SVCS), is a group of symptoms caused by obstruction of the superior vena cava ("SVC"), a short, wide vessel carrying circulating blood into the heart. The majority of cases are caused by malignant tumors within the mediastinum , most commonly lung cancer and non-Hodgkin's lymphoma , directly compressing or invading ...
A positive Pemberton's sign is indicative of superior vena cava syndrome (SVC), commonly the result of a mass in the mediastinum.Although the sign is most commonly described in patients with substernal goiters where the goiter "corks off" the thoracic inlet, [4] the maneuver is potentially useful in any patient with adenopathy, tumor, or fibrosis involving the mediastinum.
The superior vena cava (SVC) is the superior of the two venae cavae, the great venous trunks that return deoxygenated blood from the systemic circulation to the right atrium of the heart. It is a large-diameter (24 mm) short length vein that receives venous return from the upper half of the body, above the diaphragm .
Also known as “sundowner’s syndrome,” sundowning is a set of symptoms or behaviors that can be seen in some people with Alzheimer’s disease and dementia, according to the Alzheimer’s ...
Superior vena cava syndrome is a rare complication of arm DVT. [11] DVT is thought to be able to cause a stroke in the presence of a heart defect. This is called a paradoxical embolism because the clot abnormally travels from the pulmonary circuit to the systemic circuit while inside the heart.
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
It is also part of the surgical treatment path for hypoplastic left heart syndrome and hypoplastic right heart syndrome. [1] [2] [3] This procedure has been largely replaced by Bidirectional Glenn procedure. [citation needed] It connects the superior vena cava to the right pulmonary artery. [4
The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard ...